NovoCure (NVCR) Notes Payables (2024 - 2025)
NovoCure (NVCR) posted Notes Payables of $560.6 million for Q3 2025, little changed sequentially from $559.8 million in Q2 2025, and up 0.59% YoY from $557.3 million in Q3 2024.
NovoCure (NVCR) Notes Payables (2024 - 2025) Analysis & Trends
NovoCure has reported Notes Payables for 2 years, with the latest figure at $560.6 million in Q3 2025.
- Quarterly Notes Payables rose 0.59% year-over-year to $560.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $560.6 million (up 0.59% YoY) and the FY2024 annual result came in at $558.2 million, changed N/A from the prior year.
- Notes Payables was little changed at $560.6 million in Q3 2025 per NVCR's latest filing, from $559.8 million in the prior quarter.
- Over five years, Notes Payables peaked at $560.6 million in Q3 2025 and troughed at $557.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | NovoCure | 2.06 Bn | 1.62 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 560.62 Mn |
| Jun 30, 2025 | 559.79 Mn |
| Mar 31, 2025 | 558.97 Mn |
| Dec 31, 2024 | 558.16 Mn |
| Sep 30, 2024 | 557.33 Mn |